期刊
JOINT BONE SPINE
卷 85, 期 5, 页码 537-544出版社
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.jbspin.2017.11.001
关键词
Psoriatic arthritis; Spondyloarthritis; Biologics
类别
资金
- Abbvie
- Pfizer
- Roche-Chugai Bristol-Myers Squibb
- MSD
- UCB
- Novartis
- Janssen
The therapeutic management of psoriatic arthritis has seen major changes over the last few years, as illustrated by the recent updates of the GRAPPA and EULAR recommendations. These changes were driven by new studies establishing important benefits from early management and tight control of disease activity. The concepts underlying the treatment of psoriatic arthritis must be reappraised in the light of these new data. The objectives of this review are to discuss new concepts, to describe and assess the new drug classes introduced for psoriatic arthritis and, whenever possible, to define the specific indications of each class based on the rheumatic disease phenotype and presence of extra articular manifestations. (C) 2017 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据